Supplementary Tables 1-3 from A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

Autor:	Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Rok vydání:	2023
DOI:	10.1158/1078-0432.22466984
Popis:	Table S1. Treatment emergent adverse events regardless of causality in {greater than or equal to}10% of patients; Table S2. Best Overall Response; Table S3. Reasons for Emibetuzumab Discontinuation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f81cf969170c12c35f49188178d97ea https://doi.org/10.1158/1078-0432.22466984 Zobrazit plný text záznamu